Alnylam pharmaceuticals reports third quarter 2024 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the third quarter ended september 30, 2024 and reviewed recent business highlights. “alnylam continued to deliver robust results commercially and clinically in the third quarter. we achieved 34% year-over-year growth, with global net product revenues of $420 million, primarily driven by our ttr business. further with ttr, w.
ALNY Ratings Summary
ALNY Quant Ranking